RECRUITING

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

Talk to us

Conditions

Alzheimer's Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.

Official Title

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

Quick Facts

Study Start:2023-03-14
Study Completion:2029-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05658913

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 120 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Enrolled in MPC study (Protocol 850160 at UPenn; Protocol 2022P002447 at MGH).
  2. 2. Reliable study partner to accompany participant to the PET/CT scan
  3. 3. A brain MRI must be performed within 6 months prior to their study AV-1451 TAU PET/CT scan date and be deemed of adequate quality that the scan may be used for study analysis, including 3T high-resolution imaging of medial temporal lobe structures.
  1. 1. Have any medical or psychiatric conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
  2. 2. Have evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET/CT scan.
  3. 3. Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician.
  4. 4. Have a history of significant ongoing alcohol or substance abuse based on self- report.
  5. 5. Female participants of child-bearing age will not be able to participate in this study, determined by self-report.

Contacts and Locations

Study Contact

Jacqueline Lane
CONTACT
610-299-1243
Jacqueline.Lane@pennmedicine.upenn.edu

Principal Investigator

David A. Wolk
PRINCIPAL_INVESTIGATOR
University of Pennsylvania Department of Neurology at the Perelman School of Medicine
Sandhitsu R. Das
PRINCIPAL_INVESTIGATOR
University of Pennsylvania Department of Neurology at the Perelman School of Medicine

Study Locations (Sites)

Massachusetts General Hospital
Boston, Massachusetts, 02114-2696
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: University of Pennsylvania

  • David A. Wolk, PRINCIPAL_INVESTIGATOR, University of Pennsylvania Department of Neurology at the Perelman School of Medicine
  • Sandhitsu R. Das, PRINCIPAL_INVESTIGATOR, University of Pennsylvania Department of Neurology at the Perelman School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-14
Study Completion Date2029-12

Study Record Updates

Study Start Date2023-03-14
Study Completion Date2029-12

Terms related to this study

Additional Relevant MeSH Terms

  • Alzheimer's Disease